Home › Research › Treatments
Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa
Bruno Souza Fonseca, Matheus Henrique de Lima Cordeiro, Pedro Henrique Abreu, Yuji Takahashi. Revista Sociedade Científica, 2025-01-07
Topic: Amyloid, tau and blood-test diagnosis
A Doença de Alzheimer (DA) é uma condição neurodegenerativa caracterizada pela formação de placas de β-amiloide (Aβ) e emaranhados neurofibrilares no cérebro, resultando em um declínio cognitivo progressivo. Esta revisão examina as imunoterapias mais recentes direcionadas ao Aβ, com ênfase na eficácia de anticorpos monoclonais, como Aducanumab, Lecanemab e Donanemab. Uma busca através do PubMed, utilizando os operadores booleanos "((anti-amyloid antibody)) and ((Alzheimer))", inicialmente identificou 418 artigos. Após a aplicação de critérios de inclusão que exigiam revisões sistemáticas com textos completos gratuitos, publicados entre 2020 e 2024, foram examinados 6 artigos atenderam aos critérios metodológicos rigorosos necessários para descrever a eficácia e os efeitos dos anticorpos monoclonais no tratamento da DA. Embora os ensaios clínicos tenham mostrado melhorias nas escalas cognitivas, como o ADAS-Cog e o MMSE, os efeitos não atingiram um nível de relevância clínica significativa. As terapias anti-Aβ representam um avanço crucial, e espera-se que combinações futuras de tratamentos e biomarcadores aprimorem de forma mais eficaz o manejo da DA e melhorem os desfechos para os pacientes.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fonseca, B. S., Cordeiro, M. H. d. L., Abreu, P. H., & Takahashi, Y. (2025). Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa. Revista Sociedade Científica. https://doi.org/10.61411/rsc202593118
Vancouver
Fonseca BS, Cordeiro MHdL, Abreu PH, Takahashi Y. Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa. Revista Sociedade Científica. 2025. doi:10.61411/rsc202593118.
BibTeX
@article{fonseca2025-b2f98913,
author = {Fonseca, Bruno Souza and Cordeiro, Matheus Henrique de Lima and Abreu, Pedro Henrique and Takahashi, Yuji},
title = {{Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa}},
journal = {Revista Sociedade Científica},
year = {2025},
doi = {10.61411/rsc202593118},
url = {https://doi.org/10.61411/rsc202593118}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Esta revisão examina as imunoterapias mais recentes direcionadas ao Aβ, com ênfase na eficácia de anticorpos monoclonais, como Aducanumab, Lecanemab e Donanemab.
- Uma busca através do PubMed, utilizando os operadores booleanos "((anti-amyloid antibody)) and ((Alzheimer))", inicialmente identificou 418 artigos.
- Após a aplicação de critérios de inclusão que exigiam revisões sistemáticas com textos completos gratuitos, publicados entre 2020 e 2024, foram examinados 6 artigos atenderam aos critérios metodológicos rigorosos necessários para descrever a eficácia e os efeitos dos anticorpos monoclonais no tratamento da DA.
- Embora os ensaios clínicos tenham mostrado melhorias nas escalas cognitivas, como o ADAS-Cog e o MMSE, os efeitos não atingiram um nível de relevância clínica significativa.
- As terapias anti-Aβ representam um avanço crucial, e espera-se que combinações futuras de tratamentos e biomarcadores aprimorem de forma mais eficaz o manejo da DA e melhorem os desfechos para os pacientes.
Why it matters
This review of six systematic reviews found that although anti-amyloid antibodies such as aducanumab, lecanemab and donanemab improved scores on cognitive scales like ADAS-Cog and MMSE in clinical trials, the effects did not reach a level of significant clinical relevance. The authors expect that future combinations of treatments and biomarkers may improve Alzheimer's management more effectively.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Revista Sociedade Científica) |
| Journal's citation record | 0 / 4 | Revista Sociedade Científica: journal h-index 3 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Yuji Takahashi holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Universidade Federal de Goiás: institution h-index 283 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.